Foghorn Therapeutics (FHTX) Competitors $5.14 +0.16 (+3.21%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FHTX vs. SPRY, RCKT, AVDL, BCYC, COLL, SEPN, ZYME, BCAX, GYRE, and PSTXShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include ARS Pharmaceuticals (SPRY), Rocket Pharmaceuticals (RCKT), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), Septerna (SEPN), Zymeworks (ZYME), Bicara Therapeutics (BCAX), Gyre Therapeutics (GYRE), and Poseida Therapeutics (PSTX). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. ARS Pharmaceuticals Rocket Pharmaceuticals Avadel Pharmaceuticals Bicycle Therapeutics Collegium Pharmaceutical Septerna Zymeworks Bicara Therapeutics Gyre Therapeutics Poseida Therapeutics ARS Pharmaceuticals (NASDAQ:SPRY) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Does the MarketBeat Community believe in SPRY or FHTX? Foghorn Therapeutics received 19 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 82.61% of users gave ARS Pharmaceuticals an outperform vote while only 62.30% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformARS PharmaceuticalsOutperform Votes1982.61% Underperform Votes417.39%Foghorn TherapeuticsOutperform Votes3862.30% Underperform Votes2337.70% Do analysts recommend SPRY or FHTX? ARS Pharmaceuticals currently has a consensus price target of $24.00, suggesting a potential upside of 114.67%. Foghorn Therapeutics has a consensus price target of $13.80, suggesting a potential upside of 168.48%. Given Foghorn Therapeutics' higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is SPRY or FHTX more profitable? ARS Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS PharmaceuticalsN/A -22.56% -21.82% Foghorn Therapeutics -357.53%N/A -30.98% Do institutionals and insiders believe in SPRY or FHTX? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, SPRY or FHTX? ARS Pharmaceuticals has higher earnings, but lower revenue than Foghorn Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$2.57M423.10-$54.37M-$0.51-21.92Foghorn Therapeutics$25.52M11.20-$98.43M-$1.92-2.68 Which has more risk & volatility, SPRY or FHTX? ARS Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500. Does the media refer more to SPRY or FHTX? In the previous week, Foghorn Therapeutics had 14 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 20 mentions for Foghorn Therapeutics and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.76 beat Foghorn Therapeutics' score of 0.14 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryARS Pharmaceuticals beats Foghorn Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$285.75M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-2.6810.4289.5817.17Price / Sales11.20195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-2.815.094.774.78Net Income-$98.43M$151.83M$120.15M$225.60M7 Day Performance-3.02%-2.13%-1.92%-1.23%1 Month Performance-33.81%-3.10%11.47%3.36%1 Year Performance-18.15%11.54%30.54%16.60% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.8809 of 5 stars$5.14+3.2%$13.80+168.5%-14.0%$285.75M$25.52M-2.68120Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeSPRYARS Pharmaceuticals3.1441 of 5 stars$11.99+0.8%$24.00+100.2%+121.8%$1.17B$30,000.00-23.3390Insider TradeNews CoverageRCKTRocket Pharmaceuticals4.8494 of 5 stars$11.83-1.6%$51.00+331.1%-58.6%$1.08BN/A-4.37240Analyst ForecastAVDLAvadel Pharmaceuticals2.6635 of 5 stars$10.91+5.0%$24.43+123.9%-24.0%$1.05B$138.16M-13.15154Positive NewsBCYCBicycle Therapeutics3.6084 of 5 stars$15.18+9.9%$36.00+137.2%-18.8%$1.05B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeCOLLCollegium Pharmaceutical3.8414 of 5 stars$30.64+1.8%$42.60+39.0%-0.4%$988.14M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2189 of 5 stars$21.60-3.5%$43.67+102.2%N/A$959.04MN/A0.00N/AZYMEZymeworks2.8055 of 5 stars$13.74+9.2%$18.83+37.1%+52.5%$946.41M$76.01M-9.25290Analyst ForecastNews CoverageGap DownBCAXBicara TherapeuticsN/A$17.31-1.1%$43.00+148.4%N/A$941.94MN/A0.0032News CoverageGap DownGYREGyre Therapeutics0.6053 of 5 stars$9.98+3.5%N/A-61.2%$933.34M$105.03M0.0040News CoveragePositive NewsPSTXPoseida Therapeutics3.7585 of 5 stars$9.50-0.1%$9.50+193.5%$928.82M$64.70M-15.10260 Related Companies and Tools Related Companies ARS Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Bicycle Therapeutics Competitors Collegium Pharmaceutical Competitors Septerna Competitors Zymeworks Competitors Bicara Therapeutics Competitors Gyre Therapeutics Competitors Poseida Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FHTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
